<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"><channel><title><![CDATA[Innoviva, Inc. 보도자료 - 뉴스와이어]]></title><link>https://www.newswire.co.kr/?md=A10&amp;act=article&amp;no=48204></link><description><![CDATA[Innoviva, Inc. 보도자료 - 뉴스와이어 RSS 서비스]]></description><lastBuildDate>Wed, 29 Apr 2026 18:13:14 +0900</lastBuildDate><copyright>Copyright (c) 2004~2026 Korea Newswire All rights reserved</copyright><image><url><![CDATA[https://file.newswire.co.kr/data/upfile/company_img/2025/06/12_31017998_20250611084128_7099454490.png]]></url></image><language>ko-KR</language><item><title><![CDATA[Innoviva Specialty Therapeutics Receives FDA New Drug Application Acceptance for Zoliflodacin, a First-in-Class Oral Antibiotic for Uncomplicated Gonorrhea in Adults]]></title><link>https://www.newswire.co.kr/newsRead.php?no=1012845</link><description><![CDATA[WALTHAM, Mass. & GENEVA, Switzerland--(Business Wire/Korea Newswire)--Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), in collaboration with the Global Antibiotic Research &amp; Development Partnership (GARDP), today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for zoliflodacin, the investigational first-in-class, single...]]></description><pubDate>Wed, 11 Jun 2025 09:02:19 +0900</pubDate></item></channel></rss>